1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Key Pharma News 06 OCTOBER 2014

Key Pharma News 06 OCTOBER 2014

  • October 2014
  • -
  • Espicom Business Intelligence
  • -
  • 45 pages

Industry Trend Analysis - Bayer's De-Diversification Presents Opportunities For Oncology Segment
Industry Trend Analysis - Licence Agreement Helps Gilead Face Down Pressure
Industry Trend Analysis - AstraZeneca/Lilly Deal Shares Risk Over Potential Blockbuster Alzheimer's Drug
Industry Trend Analysis - Novartis Backs Away From The Fierce Nature Of HCV Market
Industry Trend Analysis - Companion Diagnostics Could See New Alzheimer's Drugs Succeed
Industry Trend Analysis - Combinations Key To Pfizer's Immuno-Oncology Success
Industry Brief - Merck Serono Enters Partnership With Lupin
Industry Trend Analysis - BI Enhances Oncology Pipeline With CureVac Agreement
Industry Trend Analysis - Next-Generation Sequencing Changing The Face Of Personalised Medicine
Industry Brief - Incyte Earns Milestone Payment Related To Jakavi's Reimbursement In Europe
Industry Trend Analysis - Alios Acquisition Boosts J&J's HCV Combination Drug Capabilities
Industry Trend Analysis - Merck KGaA On Track With Pharma Strategy
Industry Brief - Baxter Announces Name Of New Biopharmaceutical Company
Industry Trend Analysis - Daiichi Sankyo Fuels Oncology Pipeline With Ambit Acquisition
Industry Trend Analysis - Lilly's Trulicity Approval To Pave Way For Medium-Term GLP-1 Market Domination
Industry Brief - Gilead Submits NDA For LDV/SOF FDC In Japan
Industry Trend Analysis - FDA-Approved Contrave Enters Tough And Competitive Market
Industry Brief - BMS Reports Multiple Regulatory Milestones For Opdivo In US/EU
Industry Trend Analysis - Boehringer Ingelheim Close To Market With Second Oncology Drug
Industry Brief - CHMP Issues Positive Opinion On Darunavir/Cobicistat FDC
Industry Brief - FDA Panel Votes In Favour Of Liraglutide Approval For Obesity
Industry Trend Analysis - Xtandi Approval Represents Opportunity To Take Lead In MCRPCA Market
Industry Trend Analysis - Zydelig's EU Approval Puts It Temporarily Ahead Of Imbruvica
Industry Brief - FDA Approves Spiriva Respimat Inhalation Spray For COPD
Industry Trend Analysis - BMS Strikes At Merck's Keytruda With Patent Litigation
Industry Brief - Novo Nordisk's Xultophy Approved In Europe For Type II Diabetes
Industry Trend Analysis - Abilify Successor On Course For FDA Approval In 2015
Industry Brief - FDA Accepts Vyvanse sNDA For Filing With Priority Review
Industry Brief - Daiichi Sankyo Gains Japanese Approval For Additional Indications Of Lixiana
Industry Trend Analysis - Tests To FDA's Biosimilar Pathway Intensify Naming Debate
Industry Brief - Epirus Gains Indian Biosimilar Infliximab Approval
Industry Trend Analysis - Eisai Extends Aricept's Lifecycle With Japanese Approval For DLB
Industry Brief - Lundbeck Commences European Launch Of Brintellix In Denmark
Industry Brief - Shire Reaches Final Agreement With US Government
Industry Brief - FDA Approves Movantik For Treating Opioid-Induced Constipation
Industry Trend Analysis - Amgen Vies For Swift Blinatumomab Approval
Industry Trend Analysis - Litigation Threatens Namenda Switch Plan
Industry Trend Analysis - Psoriasis Approval Raises Otezla's Blockbuster Potential
Industry Brief - CHMP Adopts Positive Opinion On Gilead's Harvoni For cHCV
Industry Trend Analysis - Blood-Based Diagnostic Opens New Market For Iressa
Industry Brief - KHK Receives Japanese Approval For G-Lasta
Industry Trend Analysis - Merck Serono To Discontinue Tecemotide Development Programme In NSCLC
Industry Trend Analysis - Novo Nordisk To Invest In Obesity Research With New Unit
Industry Trend Analysis - Gilead Acts To Secure Its Reign Over HIV-1 Market
Industry Trend Analysis - Cancer Vaccine Gains First UK Promising Innovative Medicine Designation
Industry Brief - Merck Presents First Phase III Data In Japanese Patients For Omarigliptin
Industry Brief - AbbVie's Phase III Study Shows Humira's Effectiveness In Moderate-To-Severe HS
Industry Trend Analysis - Phase III MCRC Trial Results Improve Outlook For Lilly's Cyramza
Industry Brief - Secukinumab Meets Primary/Secondary Endpoints In Two Phase III PsA Studies
Industry Brief - ODM-201 Phase III Trial Initiated In Non-Metastatic Castration-Resistant PCA
Industry Brief - Novartis' LCZ696 Shows Superiority Over Enalapril In PARADIGM-HF
Industry Brief - Positive Results Reported From Four Phase III Trials Of Alirocumab
Industry Brief - LHB589 Performs Well In Phase III Combination Trials
Industry Brief - Aricept Phase III Trial In Chinese Patients With Severe AD Meets Primary Endpoint
Industry Brief - Janssen/Bayer Expand EXPLORER Cardiovascular Programme For Xarelto
Industry Brief - Positive Phase III Data Reported For Anamorelin In NSCLC Patients With Anorexia-Cachexia
Industry Brief - Byetta Meets Primary Endpoint In Trial Versus Bolus Insulin
Industry Brief - Phase III Study Of Andexanet Alfa/Eliquis Meets Primary/Secondary Endpoints

Table Of Contents

Key Pharma News 06 OCTOBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Cancer Diagnostics: A Market on the Verge of Explosion--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence

Cancer Diagnostics: A Market on the Verge of Explosion--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence

  • $ 15900
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $24,500.  DataPack (test volumes, sales forecasts, supplier shares) $15,900. VPGMarketResearch’s new report is a study of the major business opportunities emerging in the global cance ...

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

  • $ 12800
  • Industry report
  • September 2016
  • by Venture Planning Group

Complete report $19,700.  DataPack (test volumes, sales forecasts, supplier shares) $12,800. VPGMarketResearch’s new report is a study of the major business opportunities emerging in the European cance ...

R&D Drug Pipeline Database: 1-Year Subscription

R&D Drug Pipeline Database: 1-Year Subscription

  • $ 6600
  • Industry report
  • November 2016
  • by La Merie Publishing

R&D Drug Pipeline Database: 1-Year Subscription Subscription to La Merie Publishing’s proprietary R&D Drug Pieline Database provides 24/7 online access to information about more than 21,000 project entries ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.